Skip to main content
. 2018 Apr 23;19(4):1264. doi: 10.3390/ijms19041264

Table 1.

Binding affinities of VEGF-A isoforms determined at VEGFR2.

Isoform Technique Expression System Binding Affinity * Ref.
VEGF165a Radioligand binding Human kidney tissue in situ 0.01–0.04 nM [91]
HUVECs 0.17 nM [92]
Balb/c expressing VEGFR2 0.29 nM [92]
COS-1 cells expressing VEGFR2 0.34 nM [92]
PAE cells expressing VEGFR2 0.76 nM [44]
PAE cells expressing VEGFR2 0.097 nM [93]
SPR VEGFR2 ligand binding domains (D2/D3) 36.7 nM [85]
ITC VEGFR2 ligand binding domains (D2/D3) 18 nM [85]
VEGFR2 ligand binding domains (D2/D3) 170 nM [84]
VEGFR2 extracellular domain (D1–D7) 2670 nM [84]
NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.15 nM [97]
VEGF165b NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.39 nM [97]
VEGF121a ITC VEGFR2 extracellular domain (D1–D7) 1120 nM [84]
VEGFR2 ligand binding domains (D2/D3) 93 nM [84]
NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 0.34 nM [97]
VEGF145a NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 1.82 nM [97]
VEGF189a NanoBRET HEK293 cells expressing NanoLuc-VEGFR2 1.02 nM [97]

* Ligand binding affinity quantified as equilibrium dissociation constant of the “hot” ligand (Kd) or competing ligand (Ki). Abbreviations: Bioluminescence resonance energy transfer (BRET) using NanoLuciferase (NanoBRET); isothermal titration calorimetry (ITC); surface plasmon resonance (SPR).